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ABSTRACT
Common treatment options for deep vein
thrombosis and venous thromboembolism in
the pediatric population include unfractionated
heparin, low molecular weight heparin, and
warfarin. Other alternatives are bivalirudin,
argatroban, and fondaparinux. Warfarin is the
only approved oral option, but an oral agent
without frequent monitoring would be optimal
for pediatric patients. Thus, there is an
increasing need for new anticoagulation
options in this population. None of the current
direct oral anticoagulants have FDA-approved
indications and dosing in children. The two
classes of DOACs and the drugs they are
comprised of are factor Xa inhibitors
(rivaroxaban, apixaban, edoxaban) and direct
thrombin inhibitor (dabigatran). Off-label usage
of these agents is largely based on adult doses. By
far, rivaroxaban and dabigatran have the most
published data and ongoing trials in pediatric
patients compared to edoxaban and apixaban.
After evaluating the current literature available
on these agents, it is, however, still too early to
make any definitive recommendations on their




The need of anticoagulation in pediatric
patients is increasing, and certain patient
populations can be at an increased risk of
developing deep vein thrombosis (DVT) and
require venous thromboembolism (VTE)
prophylaxis or treatment [1]. In neonates,
anticoagulation is often needed when the
thromboembolism is caused by a central
venous access device or an umbilical venous
catheter. The use of anticoagulation is also
warranted in neonates with unilateral or
bilateral renal vein thrombosis that extends
into the inferior vena cava and with evidence of
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renal impairment, respectively. Many
indications exist for thromboprophylaxis in
the neonatal population, and these include
but are not limited to patients post congenital
cardiac surgery (e.g., modified Blalock–Taussig
shunts) and patients with peripheral or
umbilical arterial catheters who are at high
risk of developing clots [2].
Similarly, children may also require
anticoagulation after cardiac surgery (e.g.,
Glenn procedure or bilateral cavopulmonary
shunt). Some children with moderate or giant
coronary aneurysms following Kawasaki disease
are also warranted to be on therapeutic doses of
anticoagulants. Children with cancer are overall
at an increased risk of developing VTE and can
sometimes be seen on low molecular weight
heparin for the treatment of deep vein
thrombosis. A more detailed list of indications
for antithrombotic therapy in neonates and
childrencanbe found in theCHESTguideline [2].
Unfractionated heparin (UFH), low
molecular weight heparin (LMWH), or
warfarin is often the anticoagulant of choice
in the pediatric population [2]. If UFH and
LMWH cannot be used due to heparin-induced
thrombocytopenia and if warfarin is not an
option due to the lack of oral access, other
alternatives such as bivalirudin, argatroban, and
fondaparinux can be used. Published literature
exist in supporting the use of these three latter
anticoagulants in pediatric patients [3–10].
Lepirudin has also been studied in children
[11] but is not recommended by many
clinicians because this anticoagulant appears
to cause more bleeding in this population [12].
In recent years, direct oral anticoagulants
(DOACs) have gained interest in their potential
usage in pediatric patients. Factor Xa inhibitors
and direct thrombin inhibitor comprise the
DOACs. Rivaroxaban, apixaban, and edoxaban
are the factor Xa inhibitors and dabigatran is
the direct thrombin inhibitor. DOACs should be
avoided in patients who are pregnant and
patients with mechanical heart valves,
rheumatic mitral stenosis, and stage V chronic
kidney disease (except in patients on
stable hemodialysis who desire to be on
apixaban) [13–18]. Limited data exists on the
use of these DOACs in pediatric patients, and
none of them have Food and Drug
Administration (FDA)-approved pediatric
labeling. Off-label use of these DOACs in
pediatrics is largely extrapolated from adult
dosing guidelines. Fortunately, there are many
clinical trials currently recruiting pediatric
patients and are underway to assess their
effects and efficacy in this special population.
This article will attempt to summarize the
current data and the ongoing trials being
performed on their usage in pediatric patients.
Compliance with Ethical Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
FACTOR Xa INHIBITORS
In the coagulation cascade, factor X is
positioned at the convergence of the extrinsic
and intrinsic pathways [13]. Its activation to
factor Xa along with its binding with factor Va
to form prothrombinase is essential for the
conversion of prothrombin to thrombin [13].
Factor Xa inhibitors therefore directly decrease
the amount of thrombin being produced in
coagulation. Rivaroxaban, apixaban, and most
recently edoxaban, are oral factor Xa inhibitors
currently on the market in Europe and the
United States.
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Rivaroxaban
Rivaroxaban, the first-approved DOAC,
reversibly inhibits free and bound factor Xa as
well as that in the prothrombinase complex
ultimately preventing clot formation and
growth [19]. Rivaroxaban has been shown to
be non-inferior to low molecular weight
heparin and warfarin in multiple studies in the
adult population [20–24]. It is approved for use
in adult patients to reduce the risk of
thromboembolic complications associated
with nonvalvular atrial fibrillation (NVAF), to
treat and prevent recurrent DVT and pulmonary
embolism (PE), and for preventing DVT in
patients who underwent knee or hip
replacement surgery [14]. Dosing in adults for
the treatment and reduction in the risk of
recurrent DVT and PE is 15 mg by mouth
twice daily with food for 21 days followed by
20 mg by mouth once daily with food for the
remainder of the treatment duration [14]. Along
with the outcomes found in the adult
non-inferiority studies, rivaroxaban carries
additional advantages including once-daily
dosing, high bioavailability, minimal drug
interactions, and a limited need for laboratory
monitoring [25]. These factors make
rivaroxaban an appealing alternative to the
currently recommended anticoagulants (i.e.,
warfarin, UFH, and LMWH) in the pediatric
population.
Completed Studies
Currently, there are only four completed studies
assessing the pharmacokinetic and
pharmacodynamic (PK/PD) effects of
rivaroxaban in the pediatric population [19,
25, 26]. The first of these studies was an in vitro
analysis of the differences in the
pharmacodynamic effects of rivaroxaban in
healthy children versus adults [25]. Plasma
samples were obtained from healthy children
ages 28 days to 16 years without a family history
of coagulation disorders admitted to the
hospital for minor day surgery. Plasma samples
were grouped into age-specific pools, which
were spiked with six different concentrations of
rivaroxaban (0, 25, 50, 100, 250, and 500 ng/ml)
to match therapeutic levels of 100–300 ng/ml in
plasma. Outcomes included the differences
between measured activated partial
thromboplastin time (aPTT), prothrombin
time (PT), anti-factor Xa activity, and
endogenous thrombin potential (ETP). The
results of this trial failed to show a difference
in age-related effect of rivaroxaban on any of
the above-mentioned monitoring assays [25].
The second of these studies involved the
development of a pharmacokinetic model for
rivaroxaban 10 and 20 mg in adults scaled to
the pediatric population [19]. This study was
conducted via physiologically-based
pharmacokinetic (PBPK) simulation software,
which considered lipophilicity, hepatic and
renal clearance processes, gastrointestinal
transit and absorption, as well as the effects
food had on the medication. Using the adult
model, a pediatric model was designed that
included anthropometric and physiological
information, age-dependent clearance
processes of and protein binding in virtual
children from term neonates to adolescents
aged 18 years. Based on an average adult
weight of 70 kg, a pediatric weight-based dose
was used. These included pediatric doses of
0.143 mg/kg (1/7th mg/kg) and 0.286 mg/kg (2/
7th mg/kg), which would be equivalent to a 10-
and 20-mg dose, respectively, in adult patients.
The results of this study showed similar
maximum concentration (Cmax), area under
the curve (AUC), and 24-h concentration
(C24h) values versus body weight. In children
with body weight [70 kg, the simulated AUC
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and C24h were much higher than the adult
reference [i.e.,[90% confidence interval (CI)] so
the weight-based doses for these children may
be much higher than the 10 or 20 mg used in
adults. On the other hand, these values for
either doses (i.e., 0.143 or 0.286 mg/kg) in
infants and children up to 40 kg of body
weight were much lower than the adult
reference population (i.e.,\90% CI) so higher
doses in this weight group may be necessary
[19].
Another study was presented as an abstract at
the XXV Congress of the International Society
on Thrombosis and Haemostasis and 61st
Annual Scientific and Standardization
Committee Meeting that recently took place
in Toronto, Canada in June of 2015 [26]. The
aim of this study was to determine a dose of
rivaroxaban in pediatric patients aged
12–18 years that would result in an equivalent
exposure seen with a 20-mg dose in adult
patients for the treatment of VTE. By using a
PBPK model, a weight-adjusted dose of
rivaroxaban taken once daily was established
for the cohort. The researchers initially
performed a phase I single-dose PK/PD study
comparing the predicted and observed plasma
concentrations and AUC for the 10- (n = 4) and
20-mg (n = 5) equivalent doses. Both the
observed concentrations and the AUC were
similar to the prediction made by the PBPK
model. Dose linearity was also observed
between the 10- and 20-mg equivalent doses.
This phase I study was followed by a 30-day
multiple-dose PK/PD phase II study comparing
the predicted and observed plasma
concentrations and AUC for the 20-mg
equivalent dose and evaluating the PD
changes to the observed concentrations by
measuring markers such as PT and aPTT.
Eleven children with a mean age of 15.5 years
were enrolled in this second study. Similar to
the phase I study, the observed concentrations
and the AUC were similar to the predicted
model. Both the aPTT and PT showed an
almost-linear relationship with the drug’s
plasma concentration. No major bleeding was
observed in the study. From this data, the
researchers concluded that pediatric patients
weighing 30–50 kg will probably need 15 mg
daily and those weighing[50 kg, 20 mg daily of
rivaroxaban, for the treatment of VTE. This
dosing regimen is currently being studied in a
phase III clinical trial with a similar cohort [26].
The last of these completed studies was
recently completed and was a phase I trial
assessing the pharmacokinetic and
pharmacodynamic properties of oral
rivaroxaban in the pediatric population [27].
The subjects included in this trial were those
aged 6 months to\18 years who had completed
treatment for venous thromboembolism but
were considered to be at risk of recurrence.
These subjects were given a single dose of
weight-adjusted rivaroxaban equivalent to
10- or 20-mg dose in adults. The primary
outcomes included AUC, Cmax, PT, aPTT, and
anti-factor Xa from day 1 to day 2 post
administration of rivaroxaban. The
investigators also evaluated the safety and
tolerability of this DOAC on day 1, 2, and 7
post dose. Even though this study was
completed, the results have not yet been
published on clinicaltrials.gov [27].
Ongoing Studies
Current ongoing studies evaluating the effects
of rivaroxaban in the pediatric population
include EINSTEIN Junior which is recruiting
patients for two phase II and one phase III
studies [28–30]. There are two phase II trials
underway, which are both 30-day, open-label,
active-controlled randomized studies of the
safety/efficacy and pharmacokinetic/
22 Cardiol Ther (2016) 5:19–41
pharmacodynamic properties of oral
rivaroxaban in children with various
manifestations of venous thrombosis [28, 29].
The difference between these two studies is the
age of the participants. One of these studies
includes participants ages 6 months to\6 years
and the other includes participants ages 6 to
17 years. Participants enrolled in either trial are
those entering their last month of
anticoagulant therapy after having been
treated with LMWH, fondaparinux and/or
vitamin K antagonist (VKA) for at least
2 months or for at least 6 weeks in patients
who have had catheter-related thrombosis [28,
29].
Similarly, the phase III trial is an open-label,
active-controlled, randomized study assessing
the safety and efficacy of rivaroxaban in
comparison to the standard of care including
subcutaneous LMWH, fondaparinux and/or oral
VKA in patients with confirmed acute venous
thromboembolism [30]. Children included in
this trial are those ages 6 months to\18 years
who were initially treated with unfractionated
heparin, LMWH, or fondaparinux and required
anticoagulant therapy for at least 90 days. In
this trial, rivaroxaban will be provided
according to an age- and body weight-adjusted
dosing schedule to achieve concentrations
similar to those observed in adult patients on
20 mg of rivaroxaban. It will be provided as a
20-mg equivalent tablet given once daily for
children 12–18 years of age and subsequently as
a 20-mg equivalent oral suspension given twice
daily for children ages 6 months to \12 years
[30] (Fig. 1). The results of all of these ongoing
studies are pending and yet to be published.
Another ongoing study is a multicenter,
international, phase I study evaluating a
rivaroxaban dry powder suspension in
pediatric patients ages 6 months to 12 years
with previous history of thrombosis [31].
Subjects will be included if they have finished
treatment with an anticoagulant at least 10 days
and have normal PT and aPTT within 10 days
before enrolling into the study. The primary
outcomes will be the measurement of AUC and
Cmax 20 to 24 h after the administration of the
studied suspension. This study will also evaluate
the PT, aPTT, and anti-Xa activity of
rivaroxaban between the aforementioned
timeframe and will be compared to baseline
values that will be obtained within 5 h prior to
drug administration [31]. Similar studies
evaluating the bioavailability of a rivaroxaban
oral suspension have recently been completed
in adults. [32, 33]. It will be interesting to
compare theses adult data with the pediatric
data when they become available. Establishing a
bio-equivalent oral suspension of rivaroxaban
will be a vital step in potentially administering
this DOAC to younger pediatric patients.
The last ongoing study is both a phase I and
phase II study that will assess the safety,
efficacy, and pharmacokinetic/
pharmacodynamic properties of oral
rivaroxaban in patients less than 6 months of
age with catheter-related thrombosis who have
been treated for at least 2 weeks of standard
therapy with heparin and/or warfarin [34]. This
study will take place in 11 countries such as
Australia, France, Israel, and the United States.
The subjects will be given a 7-day treatment of
an age- and body weight-adjusted oral
rivaroxaban given twice daily as a 1-mg/ml
oral suspension to achieve similar exposures as
those observed with 20-mg daily dosing in
adults. The primary outcome will be the
plasma concentration of rivaroxaban in this
cohort from day 1 to day 8. As secondary
endpoints, the investigators will assess the
incidence of major bleeding, clinically relevant
non-major bleeding, and symptomatic
recurrent thromboembolism on days 1 to 7.
Cardiol Ther (2016) 5:19–41 23
The incidence of asymptomatic worsening of
thrombotic burden will also be evaluated on
day 8 post administration of rivaroxaban [34].
The results of all these ongoing studies will be
vital to the approval of rivaroxaban use in the
pediatric population.
Apixaban
Similar to rivaroxaban, apixaban is a reversible
factor Xa inhibitor that inhibits free, bound,
and complexed factor Xa [15]. It has gained
approval for the prevention of thromboembolic
Exclusion criteria
• Blood pressure > 95th percentile for age
• Life expectancy < 3 months
• Hypersensitive to rivaroxaban
• Currently pregnant, breast feeding, or high risk of 
pregnancy
• High bleeding risk or actively bleeding
• Concomitant use of strong inducers or inhibitors of 
CYP3A4 isoenzyme
• eGFR < 30 mL/min/1.73m2
• ALT > 5x ULN or total bilirubin > 2x ULN & direct 
bilirubin > 20% of the total
• Platelet count < 50 x 109/L
Pediatric patients meeting inclusion criteria (Estimated enrollment 
of 160 patients) 
• 6 months to < 18 years old
• Confirmed VTE & received either UFH, LMWH, or 
fondaparinux for at least 90 days
Undergoing randomization (open-label)
6 months - < 12 years: Rivaroxaban 20-mg equivalent suspension 
BID 
12 – 18 years: Rivaroxaban 20-mg equivalent tablet once daily
Standard of care: Treatment dose of either LMWH, fondaparinux, 
or warfarin
Evaluation of primary and secondary endpoints
Primary endpoints: 1) Composite number of all symptomatic recurrent VTE for up to 3 months and 2) composite number 
of overt major and clinically relevant non-major bleeding for up to 3 months
Secondary endpoint: Composite number of all symptomatic recurrent VTE and asymptomatic clots worsening on 
imaging for up to 3 months 
BID twice daily, CYP3A4 cytochrome P450 3A4, eGFR  estimated glomerular filtration rate, LMWH low molecular weight heparin, UFH
unfractionated heparin, ULN upper limit of normal, VTE venous thromboembolism   
Fig. 1 Design of oral rivaroxaban in children with venous thrombosis (EINSTEIN Junior Phase III Study) [30]
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complications in adult patients who have
undergone hip or knee replacement [35, 36]. It
was also found to be superior to warfarin for the
risk reduction of stroke and systemic embolism
in patients with atrial fibrillation [37]. Most
recently, it has been approved for the treatment
of DVT and PE and the reduction in the risk of
recurrent DVT and PE following initial therapy
[38, 39]. The recommended dosing for the
treatment of DVT and PE in adults is 10 mg by
mouth twice daily for 7 days, followed by 5 mg
by mouth twice daily [15]. Dosing for the
prevention of DVT following hip or knee
replacement surgery or for the reduction in
the risk of recurrent DVT and PE following
initial therapy is 2.5 mg by mouth twice daily
[15].
Completed Study
Currently, there are not any published trials
assessing the efficacy of apixaban in the
pediatric population. In 2012, a multi-dose
study of apixaban in the pediatric population
was terminated for unknown reasons [40]. This
study was designed to assess the
pharmacokinetic and pharmacodynamic
properties of apixaban in patients aged 12 to
\18 years with a functioning central venous
catheter. The study drug was given at a low dose
of 0.66 mg/m2 twice daily for 10 days or a high
dose of 1.32 mg/m2 as an oral solution twice
daily for 10 days [40]. No other information was
published or available on this trial and the
researchers did not mention a reason for the
early discontinuation of this study.
Ongoing Studies
To date, there are three ongoing studies
assessing the potential use of apixaban in
pediatric patients [41–44]. The first of these
studies is a phase I single-dose, parallel study
evaluating the PK and PD parameters of
apixaban as a preventive regimen in subjects
ages 37 weeks to 18 years at risk for a venous or
arterial thrombotic disorder [41]. Five different
groups are assigned in this study. Group 1
includes neonates who are given an
unspecified dose of apixaban. Group 2 is
divided into two arms: 9 months to 2 years
given 2.43 mg/m2 of apixaban and 28 days to
\9 months given 1.08 mg/m2 of the drug.
Group 3 includes patients 2 years to \6 years
old who are given a single-dose of apixaban at
1.17 mg/m2. Children ages 6 years to\12 years
are assigned to Group 4 and are given apixaban
1.8 mg/m2, whereas adolescents in Group 5 are
given 2.19 mg/m2 of apixaban. The primary
outcomes of this study include the
measurement of AUC, Cmax, and Tmax of
apixaban up to 26 h post drug administration.
As secondary outcomes, the researchers monitor
adverse events up to 26 h and 30 days post dose
and evaluate the pharmacodynamic effect of
apixaban by measuring anti-factor Xa level up
to 26 h post dose [41].
The second study was recently presented as a
poster at thepreviouslymentionedXXVCongress
of the International Society on Thrombosis and
Haemostasis and 61st Annual Scientific and
Standardization Committee Meeting [42, 43].
This is a phase III, multicenter, international,
open-label, study that randomizes pediatric
patients (ages 1 to \18 years) with acute
lymphoblastic leukemia or lymphoma treated
with L-asparaginase to either the placebo group
or the intervention group. Patients who are
2 years old and above weighing less than 35 kg
are given 0.05 mg/kg twice daily of apixaban as a
0.4 mg/ml solution and patientsweighingC35 kg
are given a 2.5-mg tablet twice daily. Per the
researchers, dosage for12–23 monthshasyet tobe
determined. Theprimary endpoint of this study is
a composite of non-fatal DVT/PE, cerebral venous
sinus thrombosis, and VTE-related death up to
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1 month after therapy. The researchers are
planning to recruit a total of 700 subjects. If this
recruitment is successful, this will be the first
adequately powered phase III clinical trial
evaluating DOAC in the pediatric population
[42, 43].
The last ongoing study will be a randomized,
phase IV, open-label study evaluating the use of
apixaban as a treatment option for acute venous
thromboembolism in pediatric patients less
than 18 years of age [44]. Subjects will be
given either the standard of care (e.g., heparin
or enoxaparin) or apixaban. Children 12 to
\18 years old weighing less than 40 kg will
receive an apixaban dose of 0.2 mg/kg twice
daily for 7 days followed by 0.1 mg/kg twice
daily, whereas children at the same age
weighing more than 40 kg will receive the
adult VTE treatment dose (i.e., 10 mg twice
daily for 7 days followed by 5 mg twice daily).
Dosages for patients less than 12 years old have
not been mentioned. The primary outcomes of
this study consist of the composite of major and
non-major bleeding and the composite of
confirmed symptomatic and asymptomatic
recurrent VTE and mortality related to the VTE
up to 12 weeks post treatment. Apixaban and
anti-Xa levels will also be obtained as secondary
endpoints. This study is estimated to be
completed in October 2020 [44] (Fig. 2).
Edoxaban
Edoxaban is the most recently approved
[January 2015 in the United States (US) and
June 2015 in Europe] factor Xa inhibitor. Even
though edoxaban does not have a novel
mechanism of action, it exhibits some
pharmacodynamic/pharmacokinetic advantages
in anticoagulation. It has the fastest time to
maximum effect (1–2 h) and offers options for
once-daily dosing and for patients with renal
impairment [45]. Also, its absorption is not
affected by the presence of food [45]. Edoxaban
is currently approved for the prevention of VTE
in patients undergoing orthopedic surgery of
the lower extremities, DVT/PE treatment
5–10 days after a parenteral anticoagulant has
been used, as well as for stroke and systemic
embolism risk reduction in NVAF. In the adult
population, 60 mg once daily is used for DVT/
PE treatment, with a dose reduction to 30 mg
once daily if the patient’s creatinine clearance is
between 15 and 50 ml/min, on a concomitant
P-glycoprotein (Pg-P) inhibitor, or weight is
B60 kg [16]. The ENGAGE AF-TIMI 48 trial
[46], which was a randomized, double-blind,
non-inferiority study of high- and low-dose
edoxaban (60 and 30 mg, respectively)
compared to warfarin, showed that edoxaban
was non-inferior to warfarin in preventing the
primary end point of systemic embolism or
stroke. In addition, edoxaban had a lower
bleeding rate and death from cardiovascular
causes in comparison to warfarin [46].
Ongoing Study
The only current pediatric study involving
edoxaban is a phase I, open-label, preliminary
pharmacodynamic and pharmacokinetic trial
in patients 0–18 years old [47]. The dose
matched to low and high adult doses (30 and
60 mg, respectively) will be given to children
requiring oral anticoagulation as a single dose.
There are currently eight arms in this study
divided by age and low/high dose of edoxaban.
The primary outcome is clearance between
days 1 and 3 post dose, and the secondary
outcomes include pharmacodynamic
parameters that are measured with PT, aPTT,
and anti-Xa levels, safety and tolerability, and
metabolite exposure. This trial is currently
recruiting patients and is expected to be
completed in 2016 [47].
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Of note, from the ENGAGE AF-TIMI 48 study
and the observation that about 50% of the dose
of edoxaban is cleared by the kidneys [46], there
is a direct correlation between serum drug levels
and outcomes expected from edoxaban (i.e.,
decrease in the risk of stroke). The ENGAGE
study proved this when it showed that patients
with NVAF with CrCL [95 ml/min had a
statistically higher rate of ischemic stroke with
edoxaban in comparison to patients receiving
warfarin. This observation resulted in a black
box warning in the US for edoxaban
Standard of care: Treatment dose of either UFH, LMWH, and/or 
warfarin
<12 years: Apixaban dose not yet determined
12 - < 18 years & ≤ 40 kg: Apixaban 0.2 mg/kg BID x 7 days, 
then 0.1 mg/kg BID
12 - < 18 years & > 40 kg: Apixaban 10 mg BID x 7 days, then 5 
mg BID
Evaluation of primary and secondary endpoints
Primary endpoints: 1) Composite number of major and clinically relevant non-major bleeding for up to 3 months and 2) 
composite number of confirmed & adjudicated symptomatic or asymptomatic recurrent VTE or related mortality for up 
to 3 months
Secondary endpoints: Apixaban concentration & anti-Xa levels on day 14
BID twice daily, LMWH low molecular weight heparin, UFH unfractionated heparin, VTE venous thromboembolism 
Pediatric patients meeting inclusion criteria (Estimated enrollment 
of 150 patients) 
• Neonates to < 18 years old
• Confirmed VTE & intending to treat with standard 
anticoagulant for at least 6 weeks in neonates & at least 
12 weeks in patients 1 month - < 18 years old
Undergoing randomization (open-label)
Exclusion criteria
• Uncontrolled severe hypertension
• Currently pregnant or breast feeding 
• High bleeding risk or actively bleeding
• Intracranial bleed within 3 months prior to randomization
• Concomitant use of prohibited medications
• Renal dysfunction
• Abnormal baseline liver function test
• Platelet count < 50 x 109/L
• Mechanical heart valve
• Thrombolytic therapy, thrombectomy, or insertion of a 
caval filter to treat the VTE
• Anticoagulant use to treat the VTE > 7 days prior to 
randomization
Fig. 2 Design of apixaban for the acute treatment of venous thromboembolism in children (Phase IV Study) [44]
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recommending healthcare providers not to use
this oral anticoagulant in patients with NVAF
whose CrCL is[95 ml/min [46]. However, this
is listed only as a precaution, not a restriction,
in the European drug label for edoxaban [17].
Even though this US warning is only in patients
with NVAF and atrial fibrillation is an irrelevant
diagnosis in pediatric patients, it will still be
interesting to assess if edoxaban will be
efficacious as an anticoagulant in this
population, especially those C2 years old, since
they very well can have a CrCL [95 ml/min/
1.73 m2 [48]. With that being said, it is,
however, not clear how the concentration of
edoxaban may relate in these two different
populations with different methods to assess
renal function so clinicians should be cautions
when trying to extrapolate this finding to
children based on normalized body surface area.
DIRECT THROMBIN INHIBITOR
Thrombin converts fibrinogen to fibrin in the
final step of the coagulation cascade. Inhibiting
this step of the coagulation cascade inhibits free
and bound thrombin, ultimately resulting in
anticoagulation [18]. Dabigatran is currently
the only oral medication in this class of
anticoagulant.
Dabigatran
In the adult population, dabigatran is approved
to treat DVT/PE as well as to reduce the risk of
stroke/systemic embolism in NVAF. Approved
doses for these indications are 150 mg twice a
day for CrCL [30 ml/min, with a dose
adjustment to 75 mg twice a day for CrCL
15–30 ml/min (i.e., for stroke reduction in
NVAF only). Dabigatran is transported via the
Pg-p efflux protein, and reaches Cmax in about
1 h if taken on an empty stomach. If given with
a high-fat meal, the Cmax increases to 2 h, but
there is not any change in the bioavailability of
the medication [18]. In the RE-LY trial, 100 and
150 mg of dabigatran were compared to
warfarin in patients with NVAF. In this study,
dabigatran was noninferior to warfarin for
stroke and systemic embolism reduction [18].
Being a direct thrombin inhibitor, dabigatran
binds to thrombin directly and is not
dependent on the availability of antithrombin
which can be very variable among patients,
specifically pediatric patients [49]. In addition,
there is also not any drug monitoring required
with dabigatran, making it also a favorable
option to explore in pediatric patients.
Completed Studies
A study was recently published assessing the
effect of dabigatran in vitro using plasma
samples and an assay with increasing
concentrations of dabigatran [1]. The five
clotting assays in this study included
thrombin time (TT), dilute thrombin time
(dTT), ecarin clotting time (ECT), aPTT, and
PT. When evaluating response to increasing
dabigatran concentrations (0, 50, 250, and
450 ng/ml), there was not any difference
among the different age groups of children (0
to\1, 1 to\5, 5 to\10, and 10 to\17 years).
However, longer clotting times with respect to
aPTT, ECT, and TT were observed in children
compared to adults with increasing
concentrations of dabigatran. Of all the assays,
the dTT, TT, and ECT were most linearly
correlated with increasing plasma
concentrations, and the study concluded that
dTT was the best assay for measuring dabigatran
concentration in pediatric patients. The author
concluded that this assay may be necessary to
measure dabigatran concentrations until there
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are more studies looking into the
pharmacodynamic and pharmacokinetic
effects of this anticoagulant in the pediatric
population [1].
Another open-label, phase II study was also
completed in February 2012 in Canada in which
the investigators aimed to evaluate the safety
and tolerability of dabigatran given for 3 days to
adolescents who had finished a course of
standard anticoagulation for the primary
diagnosis of VTE [50]. Nine subjects (mean
age, 15.7 ± 1.3 years; six of them were female)
were initially enrolled in this study. One of
these subjects did not finish the study due to
withdrawal, but he or she was included in the
final analysis. All patients were given an initial
dose of 1.71 mg/kg [75 mg (three patients);
100 mg (three patients); 125 mg (three
patients)], which was 80% of the adult 150-mg
dose adjusted for a weight of 70 kg. Thrombin
time was then obtained and the dabigatran was
adjusted to a target dose of 2.14 mg/kg twice
daily (BID) [100 mg BID (three patients);
125 mg BID (three patients); 150 mg BID (two
patients)]. None of these subjects had a major or
minor bleeding event, but two of them
experienced drug-related adverse events while
on treatment and one subject reported a serious
adverse event 72 h post-treatment (exact
descriptions of these events were not
documented). Free and total dabigatran
concentrations were also obtained in six of the
subjects. The subjects who received a final
dosage of 100 mg BID had a mean free and
total dabigatran concentration of 28 and
34.2 ng/ml, respectively; whereas the 125 mg
BID, 41.6 and 58.2 ng/ml, respectively [50].
Even though this particular study had a small
sample size, the results can potentially add to
the body of literature and provide other
investigators a plausible initial dosage of
dabigatran for adolescents involved in larger
future studies.
Ongoing Studies
Currently, there are three phase II trials being
conducted on the use of an oral dabigatran
liquid formulation in the pediatric population
[51–53]. Two of these studies aim to evaluate
the pharmacokinetic/pharmacodynamic data,
safety, and tolerability of this solution in
children who are at the end of their standard
anticoagulation course for a VTE diagnosis [51,
52]. The first study is enrolling infants less than
1 year of age (excluding\3 kg) [51], whereas the
other study is evaluating the use of this solution
in children 1 to 2 years old (excluding \9 kg)
[52]. Patients will be given an age- and
weight-adjusted equivalent dose of dabigatran.
The exact doses being used in these studies,
however, are not currently available. Some
common primary endpoints between these
two studies include the measurement of total
plasma concentrations of dabigatran, ECT, and
aPTT. The study with infants\1 year of age is
also looking at anti-factor IIa activity 2 and 12 h
post dose [51], whereas the other study is also
evaluating the incidence of bleeding and
adverse events as additional primary endpoints
[52]. The global assessment of tolerability of the
liquid medication is also being assessed as one
of the secondary endpoints [51, 52]. The last of
this phase II trial [53] has similar primary and
secondary endpoints to the one being
conducted in children 1 to 2 years old [52],
but the former is an international study and the
investigators are evaluating the use of this oral
dabigatran solution in children 1 to 12 years old
[53]. The results of all these three previously
mentioned studies are vital to establishing a
bio-equivalent oral suspension of dabigatran in
the pediatric population.
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On the other hand, there are currently two
phase III trials evaluating the safety and efficacy
of dabigatran in pediatric patients [54, 55]. The
first study is an open-label, non-inferiority
study comparing dabigatran with standard of
care (i.e., warfarin, UFH, or LMWH) to treat
patients with VTE. It has a co-primary endpoint
of thrombus resolution with freedom from
recurrent VTE in addition to freedom from
major bleeding events. The VTE must have
been diagnosed and already been treated with
UFH or LMWH for 5–7 days with an indication
to treat with anticoagulants for at least
3 months post diagnosis [54] (Fig. 3). In
another open-label study, dabigatran is being
evaluated as a secondary prophylaxis for VTE in
children ages 0–18 years [55]. The endpoints for
this study include VTE recurrence, bleeding
events (major and minor), and mortality
associated with thrombotic events. These
patients must have finished their previous
course of anticoagulants for the initial VTE to
be eligible for this study [55]. The results of all
of these ongoing studies are pending and yet to
be published. Table 1 summarizes the
information on the completed trials and those
being performed on the use of DOACs in the
pediatric population.
CLINICAL APPLICATION
Current anticoagulants recommended for the
use in pediatric patients with VTE include UFH,
LMWH, and warfarin [2]. There are several
limitations to the use of these agents that
make the DOACs desirable. Disadvantages to
the use of unfractionated heparin include the
need for continuous intravenous access and
frequent therapeutic drug level monitoring.
Although LMWH does not require intravenous
access, it requires twice-daily subcutaneous
administration, which may not be ideal for
pediatric patients who are often afraid of
needles/injections. Also, anti-Xa levels are
often required to be monitored in pediatric
patients on LMWH [2]. Finally, warfarin,
although it has the advantage of being a
once-daily oral anticoagulant, it requires
frequent international normalized ratio (INR)
monitoring and carries multiple drug and food
interactions that may require frequent dose
adjustments [56].
The DOACs, including rivaroxaban,
apixaban, dabigatran, and most recently
edoxaban, offer the possibility of improved
dose stability, oral routes of administration,
infrequent drug monitoring, and fewer drug
and food interactions [56]. A disadvantage to
the use of these agents in comparison to the
standard therapies is the lack of an established
reversal agent for pediatric patients in the case
of a major bleeding event or accidental/
intentional overdose [57]. Fortunately, it
seems that accidental or intentional one-time,
low-dose ingestion of rivaroxaban and
dabigatran does not lead to clinically
significant bleeding as demonstrated by cases
called into the California Poison Control system
from January 2011 to July 2013 [58].
Nonetheless, an effective reversal agent for
pediatric patients is indicated. Idarucizumab
was recently approved in the US in October
2015 for the reversal of dabigatran in adults
[59–61]. Currently, two additional reversal
agents are in development: andexanet alfa and
ciraparantag. Both of these agents can
potentially reverse the oral factor Xa inhibitors
as a class, and the latter may also reverse the
effect of dabigatran [62]. Even though efficacy
data on these reversal agents do not currently
exist in pediatric patients, it will be really
important for these agents to be evaluated in
this population in the near future.
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Based on the current literature, treatment of
VTE in the pediatric population should always
be initiated with UFH, LMWH, or warfarin. It is
still too early to recommend one of the DOACs
as an initial alternative for such indication due
to the lack of published clinical trials. More data
Pediatric patients meeting inclusion criteria (Estimated enrollment 
of 270 patients) 
• Neonates to < 18 years old
• Confirmed VTE with indication for 3 months of 
anticoagulation treatment 
• Treated with UFH or LMWH for 5 – 7 days 
Exclusion criteria
• Neonates to < 2 years with GA < 37 weeks or weigh < 3rd
percentile for age
• Hypersensitive to dabigatran 
• Currently pregnant, breast feeding, or high risk of 
pregnancy
• High bleeding risk or actively bleeding
• Concomitant use of prohibited medications within 1 week 
of study period
• eGFR < 80 mL/min/1.73m2 or on dialysis
• Active hepatitis 
• AST/ALT > 3x ULN within 3 months of screening
• Hemoglobin < 8 g/dL or platelet count < 80 x 109/L
(transfusion is allowed but must have normal levels prior 
to visit 2)
• Mechanical or biological heart valve
• Active infective endocarditis 
• Received an investigational drug 30 days prior
Undergoing randomization (open-label)
Dabigatran: age & weight appropriate dose BID x 3 months 
(capsules, pellets or liquid formulation)
Standard of care: Treatment dose of either LMWH or warfarin x 3 
months
Evaluation of primary and secondary endpoints
Primary endpoints: 1) Combined efficacy of complete thrombus resolution and freedom from recurrent VTE & VTE 
mortality for up to 3 months and 2) freedom from major bleeding events for up to 3 months
Secondary endpoints (major ones): Plasma concentration of dabigatran, frequency of dose adjustments, freedom from 
recurrence of VTE, all bleeding events, all-cause mortality, frequency of switching anticoagulation therapy
BID twice daily, eGFR estimated glomerular filtration rate, GA gestational age, LMWH low molecular weight heparin, UFH unfractionated
 heparin, ULN upper limit of normal, VTE venous thromboembolism 
Fig. 3 Design of the efﬁcacy and safety comparison of dabigatran etexilate to standard of care in pediatric patients with
venous thromboembolism (Phase III Study) [54]
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are needed to determine the appropriate dosing
of these agents in different age groups. For
example, the evidence available for the use of
rivaroxaban in this population only includes
the outcomes of four completed studies
assessing its pharmacokinetic and
pharmacodynamic effects in a simulated
model as well as an in vitro analysis. The
outcomes of these trials suggested that there
are minimal age-related differences in
pharmacokinetic and pharmacodynamic
effects of rivaroxaban except in children less
than 40 kg of body weight [19, 25]. In this
specific population, serum concentrations were
found to be significantly reduced, suggesting
the need for higher doses. These data also
presented that children more than 70 kg had
significantly different AUC and C24h, and
therefore, using adult-based dosing of
rivaroxaban can lead to very different
pharmacokinetic and pharmacodynamic
results in these children [19]. On the other
hand, pharmacokinetic and pharmacodynamic
results of apixaban and edoxaban should surely
drive their use in children since the available
data suggested different dosing in patients less
than 60 kg, as would be the case in most
pediatric patients. In summary, clinicians
should wait for more clinical studies to be
completed before recommending the use of
DOAC in this special population.
CONCLUSIONS
Pediatric thromboembolic complications
requiring the use of anticoagulation continues
to be a concern for this patient population
especially in regard to its associated morbidity
and mortality. Due to the lack of clinical
evidence on the use of DOACs in this
population, their use should not be considered
as first-line therapy. Instead, UFH, LMWH, or
warfarin should first be initiated. Since many
studies related to DOACs are ongoing, clinicians
should wait for them to be completed before
making any definitive recommendations on
using these agents in children. When the
results of the multiple ongoing phase III
studies are completed and published, a revised
pediatric anticoagulation guideline will surely
be warranted.
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